Acumen Pharmaceuticals

Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on the bottom line, with a Net Loss of $32.7M vs. the $21.4M mean expectation. GAAP EPS of -$0.45 was significantly below the consensus of -$0.33. Operating expenses were primarily driven by $27.8M in R&D, which, while lower YoY due to ALTITUDE-AD clinical trial cost reductions, still exceeded the implicit EBIT loss expectations. The company maintains a cash runway of $110.2M into early 2027, with the critical Phase 2 topline data for sabirnetug expected in late 2026.